The Failing Heart Relies on Ketone Bodies as a Fuel

Circulation

Volumn 133, Issue 8, 2016, Pages 698-705

  Aubert, Gregory ^a   Martin, Ola J ^a   Horton, Julie L ^a   Lai, Ling ^a   Vega, Rick B ^a   Leone, Teresa C ^a   Koves, Timothy ^b   Gardell, Stephen J ^a   Krüger, Marcus ^c   Hoppel, Charles L ^d   Lewandowski, E Douglas ^e   Crawford, Peter A ^a   Muoio, Deborah M ^b   Kelly, Daniel P ^a  

^a BURNHAM INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLOGNE   (Germany)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e UNIVERSITY OF ILLINOIS   (United States)

Author keywords

fatty acids; heart failure; hypertrophy; metabolism; molecular biology

Indexed keywords

3 HYDROXYBUTYRATE DEHYDROGENASE; FUEL; KETONE BODY; FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EX VIVO STUDY; FATTY ACID OXIDATION; FEMALE; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; ISOLATED HEART; MASS SPECTROMETRY; METABOLOMICS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE STUDY; ANIMAL; C57BL MOUSE; DIET THERAPY; GENE EXPRESSION PROFILING; KETOGENIC DIET; METABOLISM; PATHOLOGY; PROCEDURES;

ANIMALS; FATTY ACIDS; FEMALE; GENE EXPRESSION PROFILING; HEART FAILURE; KETOGENIC DIET; KETONE BODIES; MICE; MICE, INBRED C57BL;

EID: 84975775560     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.017355     Document Type: Article

References (63)

1. Bing RJ. The metabolism of the heart. Harvey Lect. 1954;50:27-70.
2. Bing RJ, Siegel A, Ungar I, Gilbert M. Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism. Am J Med. 1954;16:504-515.
3. Wisneski JA, Gertz EW, Neese RA, Mayr M. Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. J Clin Invest. 1987;79:359-366. doi: 10.1172/JCI112820.
4. Lopaschuk GD, Belke DD, Gamble J, Itoi T, Schönekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta. 1994;1213:263-276.
5. van der Vusse GJ, van Bilsen M, Glatz JF. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc Res. 2000;45:279-293.
6. Ingwall JS, Kramer MF, Fifer MA, Lorell BH, Shemin R, Grossman W, Allen PD. The creatine kinase system in normal and diseased human myocardium. N Engl J Med. 1985;313:1050-1054. doi: 10.1056/NEJM198510243131704.
7. de Roos A, Doornbos J, Luyten PR, Oosterwaal LJ, van der Wall EE, den Hollander JA. Cardiac metabolism in patients with dilated and hypertrophic cardiomyopathy: assessment with proton-decoupled P-31 MR spectroscopy. J Magn Reson Imaging. 1992;2:711-719.
8. Tian R, Nascimben L, Kaddurah-Daouk R, Ingwall JS. Depletion of energy reserve via the creatine kinase reaction during the evolution of heart failure in cardiomyopathic hamsters. J Mol Cell Cardiol. 1996;28:755-765. doi: 10.1006/jmcc.1996.0070.
9. Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res. 2004;95:135-145. doi: 10.1161/01.RES.0000137170.41939.d9.
10. Carley AN, Taegtmeyer H, Lewandowski ED. Matrix revisited: mechanisms linking energy substrate metabolism to the function of the heart. Circ Res. 2014;114:717-729. doi: 10.1161/CIRCRESAHA.114.301863.
11. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation. 1997;96:2190-2196.
12. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med. 2007;356:1140-1151. doi: 10.1056/NEJMra063052.
13. Bishop SP, Altschuld RA. Increased glycolytic metabolism in cardiac hypertrophy and congestive failure. Am J Physiol. 1970;218:153-159.
14. Taegtmeyer H, Overturf ML. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension. 1988;11:416-426.
15. Allard MF, Schönekess BO, Henning SL, English DR, Lopaschuk GD. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol. 1994;267(2 pt 2):H742-H750.
16. Christe ME, Rodgers RL. Altered glucose and fatty acid oxidation in hearts of the spontaneously hypertensive rat. J Mol Cell Cardiol. 1994;26:1371-1375. doi: 10.1006/jmcc.1994.1155.
17. Paolisso G, Gambardella A, Galzerano D, D'Amore A, Rubino P, Verza M, Teasuro P, Varricchio M, D'Onofrio F. Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism. 1994;43:174-179.
18. Sambandam N, Lopaschuk GD, Brownsey RW, Allard MF. Energy metabolism in the hypertrophied heart. Heart Fail Rev. 2002;7:161-173.
19. Chandler MP, Kerner J, Huang H, Vazquez E, Reszko A, Martini WZ, Hoppel CL, Imai M, Rastogi S, Sabbah HN, Stanley WC. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am J Physiol Heart Circ Physiol. 2004;287:H1538-H1543. doi: 10.1152/ajpheart.00281.2004.
20. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation. 1996;94:2837-2842.
21. Wallhaus TR, Taylor M, DeGrado TR, Russell DC, Stanko P, Nickles RJ, Stone CK. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation. 2001;103:2441-2446.
22. Dávila-Román VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, Gropler RJ. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2002;40:271-277.
23. de las Fuentes L, Herrero P, Peterson LR, Kelly DP, Gropler RJ, Dávila-Román VG. Myocardial fatty acid metabolism: independent predictor of left ventricular mass in hypertensive heart disease. Hypertension. 2003;41:83-87.
24. Huss JM, Imahashi K, Dufour CR, Weinheimer CJ, Courtois M, Kovacs A, Giguère V, Murphy E, Kelly DP. The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload. Cell Metab. 2007;6:25-37. doi: 10.1016/j.cmet.2007.06.005.
25. Lai L, Leone TC, Keller MP, Martin OJ, Broman AT, Nigro J, Kapoor K, Koves TR, Stevens R, Ilkayeva OR, Vega RB, Attie AD, Muoio DM, Kelly DP. Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. Circ Heart Fail. 2014;7:1022-1031. doi: 10.1161/CIRCHEARTFAILURE.114.001469.
26. Weinheimer CJ, Lai L, Kelly DP, Kovacs A. Novel mouse model of left ventricular pressure overload and infarction causing predictable ventricular remodelling and progression to heart failure. Clin Exp Pharmacol Physiol. 2015;42:33-40. doi: 10.1111/1440-1681.12318.
27. Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, Ong SE, Walford GA, Sugiana C, Boneh A, Chen WK, Hill DE, Vidal M, Evans JG, Thorburn DR, Carr SA, Mootha VK. A mitochondrial protein compendium elucidates complex I disease biology. Cell. 2008;134:112-123. doi: 10.1016/j.cell.2008.06.016.
28. Krüger M, Moser M, Ussar S, Thievessen I, Luber CA, Forner F, Schmidt S, Zanivan S, Fässler R, Mann M. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell. 2008;134:353-364. doi: 10.1016/j.cell.2008.05.033.
29. Wentz AE, d'Avignon DA, Weber ML, Cotter DG, Doherty JM, Kerns R, Nagarajan R, Reddy N, Sambandam N, Crawford PA. Adaptation of myocardial substrate metabolism to a ketogenic nutrient environment. J Biol Chem. 2010;285:24447-24456. doi: 10.1074/jbc.M110.100651.
30. Schugar RC, Moll AR, André d'Avignon D, Weinheimer CJ, Kovacs A, Crawford PA. Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling. Mol Metab. 2014;3:754-769. doi: 10.1016/j.molmet.2014.07.010.
31. Pound KM, Sorokina N, Ballal K, Berkich DA, Fasano M, Lanoue KF, Taegtmeyer H, O'Donnell JM, Lewandowski ED. Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy. Circ Res. 2009;104:805-812. doi: 10.1161/CIRCRESAHA.108.189951.
32. Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics. Circ Res. 2004;95:568-578. doi: 10.1161/01.RES.0000141774.29937.e3.
33. Cresci S, Wright LD, Spratt JA, Briggs FN, Kelly DP. Activation of a novel metabolic gene regulatory pathway by chronic stimulation of skeletal muscle. Am J Physiol. 1996;270(5 pt 1):C1413-C1420.
34. Minkler PE, Stoll MS, Ingalls ST, Kerner J, Hoppel CL. Validated method for the quantification of free and total carnitine, butyrobetaine, and acylcarnitines in biological samples. Anal Chem. 2015;87:8994-9001. doi: 10.1021/acs.analchem.5b02198.
35. Konzer A, Ruhs A, Braun T, Krüger M. Global protein quantification of mouse heart tissue based on the SILAC mouse. Methods Mol Biol. 2013;1005:39-52. doi: 10.1007/978-1-62703-386-2-4.
36. Gao Z, Xu H, DiSilvestre D, Halperin VL, Tunin R, Tian Y, Yu W, Winslow RL, Tomaselli GF. Transcriptomic profiling of the canine tachycardia-induced heart failure model: global comparison to human and murine heart failure. J Mol Cell Cardiol. 2006;40:76-86. doi: 10.1016/j. yjmcc.2005.08.002.
37. Bugger H, Schwarzer M, Chen D, Schrepper A, Amorim PA, Schoepe M, Nguyen TD, Mohr FW, Khalimonchuk O, Weimer BC, Doenst T. Proteomic remodelling of mitochondrial oxidative pathways in pressure overload-induced heart failure. Cardiovasc Res. 2010;85:376-384. doi: 10.1093/cvr/cvp344.
38. Barth AS, Kumordzie A, Frangakis C, Margulies KB, Cappola TP, Tomaselli GF. Reciprocal transcriptional regulation of metabolic and signaling pathways correlates with disease severity in heart failure. Circ Cardiovasc Genet. 2011;4:475-483. doi: 10.1161/CIRCGENETICS.110.957571.
39. Xu J, Nie HG, Zhang XD, Tian Y, Yu B. Down-regulated energy metabolism genes associated with mitochondria oxidative phosphorylation and fatty acid metabolism in viral cardiomyopathy mouse heart. Mol Biol Rep. 2011;38:4007-4013. doi: 10.1007/s11033-010-0519-y.
40. Taegtmeyer H, Golfman L, Sharma S, Razeghi P, van Arsdall M. Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann N Y Acad Sci. 2004;1015:202-213. doi: 10.1196/annals.1302.017.
41. Akki A, Smith K, Seymour AM. Compensated cardiac hypertrophy is characterised by a decline in palmitate oxidation. Mol Cell Biochem. 2008;311:215-224. doi: 10.1007/s11010-008-9711-y.
42. Ardehali H, Sabbah HN, Burke MA, Sarma S, Liu PP, Cleland JG, Maggioni A, Fonarow GC, Abel ED, Campia U, Gheorghiade M. Targeting myocardial substrate metabolism in heart failure: potential for new therapies. Eur J Heart Fail. 2012;14:120-129. doi: 10.1093/eurjhf/hfr173.
43. Kolwicz SC Jr, Olson DP, Marney LC, Garcia-Menendez L, Synovec RE, Tian R. Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circ Res. 2012;111:728-738. doi: 10.1161/CIRCRESAHA.112.268128.
44. Lewandowski ED, Fischer SK, Fasano M, Banke NH, Walker LA, Huqi A, Wang X, Lopaschuk GD, O'Donnell JM. Acute liver carnitine palmitoyltransferase I overexpression recapitulates reduced palmitate oxidation of cardiac hypertrophy. Circ Res. 2013;112:57-65. doi: 10.1161/CIRCRESAHA.112.274456.
45. Sorokina N, O'Donnell JM, McKinney RD, Pound KM, Woldegiorgis G, LaNoue KF, Ballal K, Taegtmeyer H, Buttrick PM, Lewandowski ED. Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts. Circulation. 2007;115:2033-2041. doi: 10.1161/CIRCULATIONAHA.106.668665.
46. Hack A, Busch V, Pascher B, Busch R, Bieger I, Gempel K, Baumeister FA. Monitoring of ketogenic diet for carnitine metabolites by subcutaneous microdialysis. Pediatr Res. 2006;60:93-96. doi: 10.1203/01. pdr.0000219479.95410.79.
47. Soeters MR, Serlie MJ, Sauerwein HP, Duran M, Ruiter JP, Kulik W, Ackermans MT, Minkler PE, Hoppel CL, Wanders RJ, Houten SM. Characterization of D-3-hydroxybutyrylcarnitine (ketocarnitine): an identified ketosis-induced metabolite. Metabolism. 2012;61:966-973. doi: 10.1016/j.metabol.2011.11.009.
48. DeBalsi KL, Wong KE, Koves TR, Slentz DH, Seiler SE, Wittmann AH, Ilkayeva OR, Stevens RD, Perry CG, Lark DS, Hui ST, Szweda L, Neufer PD, Muoio DM. Targeted metabolomics connects thioredoxin-interacting protein (TXNIP) to mitochondrial fuel selection and regulation of specific oxidoreductase enzymes in skeletal muscle. J Biol Chem. 2014;289:8106-8120. doi: 10.1074/jbc.M113.511535.
49. Hasselbaink DM, Glatz JF, Luiken JJ, Roemen TH, Van der Vusse GJ. Ketone bodies disturb fatty acid handling in isolated cardiomyocytes derived from control and diabetic rats. Biochem J. 2003;371(pt 3):753-760. doi: 10.1042/BJ20021617.
50. Stanley WC, Meadows SR, Kivilo KM, Roth BA, Lopaschuk GD. beta-Hydroxybutyrate inhibits myocardial fatty acid oxidation in vivo independent of changes in malonyl-CoA content. Am J Physiol Heart Circ Physiol. 2003;285:H1626-H1631. doi: 10.1152/ajpheart.00332.2003.
51. Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fatty Acids. 2004;70:309-319. doi: 10.1016/j. plefa.2003.09.007.
52. Tian Q, Barger PM. Deranged energy substrate metabolism in the failing heart. Curr Hypertens Rep. 2006;8:465-471.
53. Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J Clin Invest. 2000;105:1723-1730. doi: 10.1172/JCI9056.
54. Lahey R, Wang X, Carley AN, Lewandowski ED. Dietary fat supply to failing hearts determines dynamic lipid signaling for nuclear receptor activation and oxidation of stored triglyceride. Circulation. 2014;130:1790-1799. doi: 10.1161/CIRCULATIONAHA.114.011687.
55. Rudolph W, Maas D, Richter J, Hasinger F, Hofmann H, Dohrn P. [On the significance of acetoacetate and beta-hydroxybutyrate in human myocardial metabolism]. Klin Wochenschr. 1965;43:445-451.
56. Jeffrey FM, Diczku V, Sherry AD, Malloy CR. Substrate selection in the isolated working rat heart: effects of reperfusion, afterload, and concentration. Basic Res Cardiol. 1995;90:388-396.
57. Bartelds B, van der Leij FR, Kuipers JR. Role of ketone bodies in perinatal myocardial energy metabolism. Biochem Soc Trans. 2001;29(pt 2):325-330.
58. Russell RR 3rd, Taegtmeyer H. Changes in citric acid cycle flux and anaplerosis antedate the functional decline in isolated rat hearts utilizing acetoacetate. J Clin Invest. 1991;87:384-390. doi: 10.1172/JCI115008.
59. Kupari M, Lommi J, Ventilä M, Karjalainen U. Breath acetone in congestive heart failure. Am J Cardiol. 1995;76:1076-1078.
60. Chung JH, Kim JS, Kim OY, Kang SM, Hwang GS, Shin MJ. Urinary ketone is associated with the heart failure severity. Clin Biochem. 2012;45:1697-1699. doi: 10.1016/j.clinbiochem.2012.08.013.
61. Marcondes-Braga FG, Gutz IG, Batista GL, Saldiva PH, Ayub-Ferreira SM, Issa VS, Mangini S, Bocchi EA, Bacal F. Exhaled acetone as a new biomaker of heart failure severity. Chest. 2012;142:457-466. doi: 10.1378/chest.11-2892.
62. Samara MA, Tang WH, Cikach F Jr, Gul Z, Tranchito L, Paschke KM, Viterna J, Wu Y, Laskowski D, Dweik RA. Single exhaled breath metabolomic analysis identifies unique breathprint in patients with acute decompensated heart failure. J Am Coll Cardiol. 2013;61:1463-1464. doi: 10.1016/j.jacc.2012.12.033.
63. Lommi J, Kupari M, Koskinen P, Näveri H, Leinonen H, Pulkki K, Härkönen M. Blood ketone bodies in congestive heart failure. J Am Coll Cardiol. 1996;28:665-672.